Anti-CD45 antibody [MEM-28] (ab8216)
Key features and details
- Mouse monoclonal [MEM-28] to CD45
- Suitable for: Flow Cyt, IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG1
Related conjugates and formulations
Overview
-
Product name
Anti-CD45 antibody [MEM-28]
See all CD45 primary antibodies -
Description
Mouse monoclonal [MEM-28] to CD45 -
Host species
Mouse -
Specificity
Human CD45 antigen (LCA). This antibody reacts with all alternative forms of CD45. -
Tested applications
Suitable for: Flow Cyt, IHC-P, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human CD45. Human thymocytes and T lymphocytes.
-
Positive control
- IHC-P: Human tonsil tissue. Flow Cyt: Human peripheral blood mononuclear cells. ICC/IF: Human peripheral blood mononuclear cells.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.097% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
MEM-28 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
- FITC Anti-CD45 antibody [MEM-28], prediluted (ab134199)
- PE Anti-CD45 antibody [MEM-28], prediluted (ab134202)
- PerCP/Cy5.5® Anti-CD45 antibody [MEM-28] (ab157309)
- APC/Cy7® Anti-CD45 antibody [MEM-28] (ab197130)
- PE/DyLight™ 594 Anti-CD45 antibody [MEM-28] (ab223183)
- Alexa Fluor® 647 Anti-CD45 antibody [MEM-28] (ab239276)
- PE/Cy7® Anti-CD45 antibody [MEM-28] (ab239317)
- APC Anti-CD45 antibody [MEM-28] (ab28106)
- Biotin Anti-CD45 antibody [MEM-28] (ab28107)
- PerCP Anti-CD45 antibody [MEM-28] (ab65952)
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab8216 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use 1µg for 106 cells.
(Recognizes an extracellular epitope). |
|
IHC-P | (1) |
Use a concentration of 1 µg/ml. Antigen retrieval is not essential but may optimise staining.
|
ICC/IF |
Use a concentration of 10 µg/ml.
PFA fixation can be used |
Notes |
---|
Flow Cyt
Use 1µg for 106 cells. (Recognizes an extracellular epitope). |
IHC-P
Use a concentration of 1 µg/ml. Antigen retrieval is not essential but may optimise staining. |
ICC/IF
Use a concentration of 10 µg/ml. PFA fixation can be used |
Target
-
Function
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. -
Involvement in disease
Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. -
Sequence similarities
Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains. -
Domain
The first PTPase domain interacts with SKAP1. -
Post-translational
modificationsHeavily N- and O-glycosylated. -
Cellular localization
Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts. - Information by UniProt
-
Database links
- Entrez Gene: 5788 Human
- Omim: 151460 Human
- SwissProt: P08575 Human
- Unigene: 654514 Human
-
Alternative names
- B220 antibody
- CD 45 antibody
- CD45 antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-CD45 antibody [MEM-28] (ab8216)Image from Nel, Ivonne et al. PLoS ONE 11.4 (2016): e0153018. doi: 10.1371/journal.pone.0153018 Fig 3.
Immunocytochemistry/ Immunofluorescence analysis of CTC isolated from mRCC patients stained for hematopoietic cells labeling CD45 with ab8216 (green). The cells were fixed in 4.5% paraformaldehyde for 15 min, washed in PBS, permeabilized with 1x Perm/Wash for 10 min, washing in PBS, blocking of unspecific antibody reactions by incubation with blocking solution containing 5% BSA for 30 min, binding of Anti-CD45 antibody [MEM-28] (ab8216) (final concentration: 5 μg/ml) overnight at 4°C, wash in 0,1% Tween, binding of secondary antibody (Cy3-conjugated goat anti-mouse) for 30 min at 37°C, washing in 0,1% Tween. Subsequently, cells were stained with DAPI for 10 min, mounted with anti-fading medium and stored in the dark until evaluation. Left: CD45, right: DAPI, bottom: merge.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45 antibody [MEM-28] (ab8216)Ab8216 staining human normal tonsil tissue. Staining is localised to cellular membranes.
Left panel: with primary antibody at 1 ug/ml. Right panel: isotype control.
Sections were stained using an automated system (DAKO Autostainer Plus ), at room temperature: sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffers citrate pH6.1 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required. -
Flow cytometry analysis (surface staining) of human peripheral blood cells with ab8216 (1 ug/ml), GAM-APC.
-
Immunocytochemistry/ Immunofluorescence - Anti-CD45 antibody [MEM-28] (ab8216)Image from Weller, Patrick et al. PLoS ONE 9.12 (2014): e113706. doi: 10.1371/journal.pone.0113706. Fig 2. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/
Immunocytochemistry/ Immunofluorescence analysis of citrated peripheral blood hematologic cells taken from head and neck squamous cell carcinoma (HNSCC) patients labeling CD45 with ab8216 (green). The staining method included fixation of the cells in 4.5% paraformaldehyde for 15 min, washing in PBS, permeabilization with 1× Perm/Wash Buffer for 10 min, washing in PBS, blocking of unspecific antibody reactions by incubation with blocking solution containing 5% BSA for 30 min, binding of Anti-CD45 antibody [MEM-28] (ab8216) (final concentration: 5 µg/ml) overnight at 4°C, wash in 0,1% Tween, binding of Cy3-conjugated secondary antibody for 30 min at 37°C, washing in 0,1% Tween.
-
Immunocytochemistry/ Immunofluorescence - Anti-CD45 antibody [MEM-28] (ab8216)Image from Nel, Ivonne et al. PLoS ONE 11.4 (2016): e0153018. doi: 10.1371/journal.pone.0153018 Fig 2. Reproduced under the Creative Commons license http://creativecommons.org/licenses/by/4.0/
Immunocytochemistry/ Immunofluorescence analysis of hematopoietic cells labeling CD45 with ab8216. The cells were fixed in 4.5% paraformaldehyde for 15 min, washed in PBS, permeabilized with 1x Perm/Wash for 10 min, washing in PBS, blocking of unspecific antibody reactions by incubation with blocking solution containing 5% BSA for 30 min, binding of Anti-CD45 antibody [MEM-28] (ab8216) (final concentration: 5 μg/ml) overnight at 4°C, wash in 0,1% Tween, binding of secondary antibody (Cy3-conjugated goat anti-mouse) for 30 min at 37°C, washing in 0,1% Tween.
-
Overlay histogram showing peripheral blood lymphocytes stained with ab8216 (red line). The cells were incubated with the antibody (ab8216, 1µg/1x106 cells) for 30 min at 4ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H&L) (ab96879) at 1/200 dilution for 30 min at 4ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed gating on peripheral blood lymphocytes.
-
Immunocytochemistry/Immunofluorescence analysis of human peripheral blood mononuclear cells labelling CD45 (green) with ab8216 at 10 μg/mL. Nuclei were counterstained with DAPI (blue).
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (38)
ab8216 has been referenced in 38 publications.
- Qiao T et al. Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model. Front Oncol 11:632364 (2021). PubMed: 33859941
- Choi YW et al. Senescent Tumor Cells Build a Cytokine Shield in Colorectal Cancer. Adv Sci (Weinh) 8:2002497 (2021). PubMed: 33643790
- Puttipanyalears C et al. Quantitative STAU2 measurement in lymphocytes for breast cancer risk assessment. Sci Rep 11:915 (2021). PubMed: 33441653
- Duplancic R & Kero D Novel approach for quantification of multiple immunofluorescent signals using histograms and 2D plot profiling of whole-section panoramic images. Sci Rep 11:8619 (2021). PubMed: 33883639
- Han AR et al. Distinct Repopulation Activity in Hu-Mice Between CB- and LPB-CD34+ Cells by Enrichment of Transcription Factors. Int J Stem Cells 14:203-211 (2021). PubMed: 33906982